Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study
about
Placebos without deception: a randomized controlled trial in irritable bowel syndromeBulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndromeComplementary and alternative medicine for treatment of irritable bowel syndromeMycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicitiesPsychosocial impact of irritable bowel syndrome: A brief reviewAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideThe low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study.Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.Methodological issues in the study of intestinal microbiota in irritable bowel syndromeTrauma history and risk of the irritable bowel syndrome in women veterans.Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective oA protocol for a trial of homeopathic treatment for irritable bowel syndrome.Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome.Nutrition economics - characterising the economic and health impact of nutrition.Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome.A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations.Snapshot of an integrated psychosocial gastroenterology serviceThe spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burdenMaladjustment to Academic Life and Employment Anxiety in University Students with Irritable Bowel Syndrome.Change in Quality of Life for Patients with Irritable Bowel Syndrome following Referral to a Gastroenterologist: A Cohort StudyPerceived food intolerance and irritable bowel syndrome in a population 3 years after a giardiasis-outbreak: a historical cohort study.SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.Changes in Intestinal Motility and Gut Microbiota Composition in a Rat Stress Model.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.The microbiota link to irritable bowel syndrome: an emerging storyA 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationHealth-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthoodThe trials and tribulations of drug development for functional gastrointestinal disorders.Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort.Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study.Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic surveyCurrent and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
P2860
Q21091076-3F7A67A1-640A-4677-9BE3-B36623B2789FQ24234934-60C0D336-7530-409A-A727-DAB0894F0559Q24653574-02D5253A-46DA-442C-8A2A-FC51CCE4E647Q24681823-AE51F6BB-99E2-4BA2-A5D5-0BD92D60875CQ26776175-583BC4D8-69A8-4946-88B2-6E020E9E53D8Q26865304-C2C6E505-CEA7-41B6-B0A4-D97096495445Q33458071-7071A611-2E83-46B4-BC0F-BBC0BF891B07Q33628494-DEBD296F-E200-49E5-8141-549FE1D65DC2Q33639963-6815B400-5FFD-448A-91F6-8749827ADBB6Q33781174-036FBA76-6386-4020-B588-0C22CE24076BQ33887153-BB975BFD-5677-4F83-9BDE-0B849305CDF4Q33958776-BBE51289-02FD-4078-9FF5-B6844BC8FF03Q34005405-1F26A438-3DC3-4FD6-8D15-B06C02F85C50Q34179472-F951B516-693F-4D69-A9A1-7BEFB2BA695FQ34392861-6AB9CB43-CB72-43D7-8DD1-E12BB3010DF8Q34410818-CED243DE-25DA-4353-9E1D-60CAF0543D69Q34468338-CD12991F-57F6-4CB0-9AD2-A02A7A4D89F2Q34473213-DA133185-F65F-4000-9126-7673BF3F32E0Q34501500-D4D8AFAD-D2B2-4E28-9F2C-C2131262403DQ34606239-3974E583-0668-4C26-ACA5-7E1E0C029EFEQ35000565-CFF7249A-3799-4D96-8323-ADF100C0234AQ35069505-9CFB706C-95D8-4F22-9A49-216AF9F68BFFQ35583291-70B7DB77-2426-435E-8953-4684251574E0Q35666286-6A024F28-4B36-41BB-B1AF-73A61CD08D59Q35797307-4E894DF8-B8B9-461C-8C84-46C5BE63C0A4Q35846558-39AE8068-E79E-44E0-96DE-D60FF3EB7293Q35867796-533C0FE1-15A4-4EE7-87B1-0134FFC10E1BQ35929170-7EE4FD97-50D0-4BC7-908A-B51CDCD1F9B9Q36239616-CD578255-3603-486D-9B90-C71E7440085DQ36297736-606A8A1B-92B5-498D-B766-CEE3361A33ADQ36392101-1448F06A-2C13-49C8-9ED6-1932BAC290EFQ36417684-D9F65417-AF3C-497A-A516-8933705FBB09Q37127365-88AE65DA-4A20-439A-8FE0-694F6D03813CQ37134572-965EA855-F20A-4768-AED8-48D4E61762F0Q37340278-DE2B9911-BE2D-48F3-A3AF-ECCB2E615D4AQ37405874-F177E2A8-AD2A-41FC-B149-C665145EC703Q37542854-76D2DB62-111E-4126-BF35-238FE9BAEB31Q37632259-17D09C09-DBAA-4F22-9C26-98B2A0B64BB5Q37642924-8BF5F021-1722-4338-A740-188ECA3C0C3CQ37654528-AB94C7EA-BA28-461D-A392-309A0DAEBB56
P2860
Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Health-related quality of life ...... Canada), a naturalistic study
@ast
Health-related quality of life ...... Canada), a naturalistic study
@en
Health-related quality of life ...... Canada), a naturalistic study
@nl
type
label
Health-related quality of life ...... Canada), a naturalistic study
@ast
Health-related quality of life ...... Canada), a naturalistic study
@en
Health-related quality of life ...... Canada), a naturalistic study
@nl
prefLabel
Health-related quality of life ...... Canada), a naturalistic study
@ast
Health-related quality of life ...... Canada), a naturalistic study
@en
Health-related quality of life ...... Canada), a naturalistic study
@nl
P2093
P1476
Health-related quality of life ...... Canada), a naturalistic study
@en
P2093
Christopher R McBurney
James Gray
Martin Barbeau
Pierre Paré
Shideh Khorasheh
Suzanne Kelly
P304
1726-35; discussion 1710-1
P356
10.1016/J.CLINTHERA.2006.10.010
P577
2006-10-01T00:00:00Z